VCYT Veracyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCYT

Price (delayed)

$19.58

Market cap

$1.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.02

Enterprise value

$1.27B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's gross profit has increased by 27% YoY and by 7% QoQ
Veracyte's revenue has increased by 22% YoY and by 5% QoQ
Veracyte's net income has shrunk by 104% YoY and by 49% QoQ
The EPS has dropped by 100% year-on-year and by 48% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.veracyte.com
Peers: MYGN EXAS CYTK BIIB

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
75.07M
Market cap
$1.47B
Enterprise value
$1.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.37
Price to sales (P/S)
3.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
Earnings
Revenue
$361.05M
EBIT
-$76.61M
EBITDA
-$45.27M
Free cash flow
$34.26M
Per share
EPS
-$1.02
Free cash flow per share
$0.47
Book value per share
$14.29
Revenue per share
$4.97
TBVPS
$4.45
Balance sheet
Total assets
$1.11B
Total liabilities
$70.8M
Debt
$12.63M
Equity
$1.04B
Working capital
$224.38M
Liquidity
Debt to equity
0.01
Current ratio
4.66
Quick ratio
4.21
Net debt/EBITDA
4.52
Margins
EBITDA margin
-12.5%
Gross margin
68.7%
Net margin
-20.6%
Operating margin
-23.8%
Efficiency
Return on assets
-6.5%
Return on equity
-7%
Return on invested capital
-124%
Return on capital employed
-7.3%
Return on sales
-21.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
-1.61%
1 week
1.98%
1 month
-6.76%
1 year
-11.32%
YTD
-28.83%
QTD
-11.64%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$361.05M
Gross profit
$248.15M
Operating income
-$85.8M
Net income
-$74.4M
Gross margin
68.7%
Net margin
-20.6%
The operating income has plunged by 109% YoY and by 54% from the previous quarter
Veracyte's net income has shrunk by 104% YoY and by 49% QoQ
The operating margin has plunged by 71% YoY and by 47% from the previous quarter
The net margin has plunged by 67% YoY and by 41% from the previous quarter

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
1.37
P/S
3.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.5
The EPS has dropped by 100% year-on-year and by 48% since the previous quarter
The P/B is 58% below the 5-year quarterly average of 3.3 and 18% below the last 4 quarters average of 1.7
The equity has contracted by 2.9% YoY
The P/S is 64% below the 5-year quarterly average of 11.1 and 25% below the last 4 quarters average of 5.3
Veracyte's revenue has increased by 22% YoY and by 5% QoQ

Efficiency

How efficient is Veracyte business performance
VCYT's return on invested capital has dropped by 139% year-on-year and by 70% since the previous quarter
The company's return on equity has shrunk by 106% YoY and by 49% QoQ
The ROA has plunged by 103% YoY and by 51% from the previous quarter
The return on sales has dropped by 72% year-on-year and by 47% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The company's quick ratio rose by 18% YoY
The company's current ratio rose by 17% YoY
The debt is 99% less than the equity
The debt has contracted by 14% YoY and by 8% from the previous quarter
The equity has contracted by 2.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.